Literature DB >> 23436853

ADC values and prognosis of malignant astrocytomas: does lower ADC predict a worse prognosis independent of grade of tumor?--a meta-analysis.

Maria Zulfiqar1, David M Yousem, Hong Lai.   

Abstract

OBJECTIVE: The purpose of this article is to determine via meta-analysis whether apparent diffusion coefficient (ADC) predicts astrocytoma prognosis independent of grade.
MATERIALS AND METHODS: Survival data were subjected to Mantel Haenszel analysis in four qualifying studies. Stratification by tumor grade was also performed.
RESULTS: The survival rates of malignant astrocytomas, grade 3 and 4 (p, 0.004 and < 0.0001, respectively) were worse below a specific ADC value, independent of grade.
CONCLUSION: Low ADC values correlate with poor survival in malignant astrocytomas independent of tumor grade.

Entities:  

Mesh:

Year:  2013        PMID: 23436853     DOI: 10.2214/AJR.12.8679

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  28 in total

1.  MR imaging phenotype correlates with extent of genome-wide copy number abundance in IDH mutant gliomas.

Authors:  Chih-Chun Wu; Rajan Jain; Lucidio Neto; Seema Patel; Laila M Poisson; Jonathan Serrano; Victor Ng; Sohil H Patel; Dimitris G Placantonakis; David Zagzag; John Golfinos; Andrew S Chi; Matija Snuderl
Journal:  Neuroradiology       Date:  2019-05-27       Impact factor: 2.804

2.  [Towards more precision in the therapy of brain tumors. Possibilities and limits of MRI].

Authors:  A Radbruch; E Hattingen
Journal:  Nervenarzt       Date:  2015-06       Impact factor: 1.214

3.  Apparent diffusion coefficient maps obtained from high b value diffusion-weighted imaging in the preoperative evaluation of gliomas at 3T: comparison with standard b value diffusion-weighted imaging.

Authors:  Qiang Zeng; Fei Dong; Feina Shi; Chenhan Ling; Biao Jiang; Jianmin Zhang
Journal:  Eur Radiol       Date:  2017-06-21       Impact factor: 5.315

4.  Prognostic relevance of gemistocytic grade II astrocytoma: gemistocytic component and MR imaging features compared to non-gemistocytic grade II astrocytoma.

Authors:  Young Jin Heo; Ji Eun Park; Ho Sung Kim; Ji Ye Lee; Soo Jeong Nam; Seung Chai Jung; Choong Gon Choi; Sang Joon Kim
Journal:  Eur Radiol       Date:  2016-11-17       Impact factor: 5.315

5.  Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival.

Authors:  Valeria Cuccarini; A Erbetta; M Farinotti; L Cuppini; F Ghielmetti; B Pollo; F Di Meco; M Grisoli; G Filippini; G Finocchiaro; M G Bruzzone; M Eoli
Journal:  J Neurooncol       Date:  2016-01       Impact factor: 4.130

6.  Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan.

Authors:  Domenico Aquino; Anna Luisa Di Stefano; Alessandro Scotti; Lucia Cuppini; Elena Anghileri; Gaetano Finocchiaro; Maria Grazia Bruzzone; Marica Eoli
Journal:  PLoS One       Date:  2014-03-27       Impact factor: 3.240

7.  Evaluation of absolute and normalized apparent diffusion coefficient (ADC) values within the post-operative T2/FLAIR volume as adverse prognostic indicators in glioblastoma.

Authors:  Andrew Elson; Joseph Bovi; Malika Siker; Chris Schultz; Eric Paulson
Journal:  J Neurooncol       Date:  2015-02-21       Impact factor: 4.130

Review 8.  Clinical applications for diffusion magnetic resonance imaging in radiotherapy.

Authors:  Christina Tsien; Yue Cao; Thomas Chenevert
Journal:  Semin Radiat Oncol       Date:  2014-07       Impact factor: 5.934

9.  Lower apparent diffusion coefficients indicate distinct prognosis in low-grade and high-grade glioma.

Authors:  Yong Cui; Li Ma; Xuzhu Chen; Zhe Zhang; Haihui Jiang; Song Lin
Journal:  J Neurooncol       Date:  2014-05-30       Impact factor: 4.130

10.  Remodeling the Vascular Microenvironment of Glioblastoma with α-Particles.

Authors:  Katja Behling; William F Maguire; Valentina Di Gialleonardo; Lukas E M Heeb; Iman F Hassan; Darren R Veach; Kayvan R Keshari; Philip H Gutin; David A Scheinberg; Michael R McDevitt
Journal:  J Nucl Med       Date:  2016-06-03       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.